Compare Ross Stores, Inc. (ROST) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Ross Stores, Inc. trades at $230.66 (market cap $72.09B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Ross Stores, Inc. is far larger — about 14.8× Travere Therapeutics Inc. Common Stock's market cap, and Ross Stores, Inc. pays a 0.79% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ross Stores, Inc. for 48 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ROST | TVTX | |
|---|---|---|
Market Cap | $72.09B | $4.88B |
Volume | 1,593,708 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $255.23 | $67.52 |
52-Week Low | $155.21 | $26.79 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $72.55B | $5.01B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $230.57, up 2.09% today, showing strong momentum with three consecutive earnings beats. The stock faces technical headwinds with a bearish signal but maintains robust fundamentals including 42.63% ROE and 10.85% net margins. Recent news highlights store expansion initiatives and strong closeout supply positioning the company to capture value-conscious consumer demand.
ROST presents a compelling investment case with analyst consensus target of $274.14 (19% upside) and strong institutional support. However, near-term technical weakness and competitive pressures in discount retail require monitoring. The company's consistent earnings outperformance and expanding margins support long-term growth prospects despite current market volatility.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
